A prominent pharmaceutical company, deeply invested in neurodegenerative research, aimed to understand the underlying molecular mechanisms of Alzheimer’s disease wanted an efficient, yet detailed method to interpret microarray data in published literature and map the intricate molecular interactions that lead to Alzheimer’s disease.